Deadline: 12-Jun-25
Submissions are now open for the Pfizer Fellowship Grant program to increase the number of fellowship programs for hematologists specializing in treating adults with sickle cell disease (SCD).
Area of Interest
- It is the intent to support institutions with fellowship programs for hematologists who specialize in treating adults with SCD that have a strong focus on clinical practice, research, and education to further the understanding of SCD.
- Grants will be available for both established and emerging SCD Fellowship programs.
- Grants will be awarded based on the strength of the requesting organization’s ability to provide expert mentorship, training, and guidance to the fellow.
Funding Information
- Grant funding is available to support a one-year fellowship up to $80,000.
Eligibility Criteria
- Accredited, US-based academic institution.
- Do not include the name of the potential fellow(s) in application materials. This grant will be awarded to an institution, not an individual.
- Institutions with fellowship programs that include independent research and a strong mentoring program. Clinical training may be included in the program but is not required.
- No aspect of the fellowship program can benefit Pfizer’s business or a Pfizer asset.
- Examples of independent research include: observational studies and outcomes research studies where the primary focus is the scientific understanding of disease; use of screening tools and their impact on improvement of patient health.
- Examples of research that would not be eligible include research involving the study and/or evaluation of any pharmaceutical product and basic science and/or fundamental research (in animal model, in-vitro, etc.).
- Examples of clinical training include: educational time with an interdisciplinary team in review of case examples and relevant didactic training as well as use of tools for improvement in patient health for specific therapeutic areas or conditions.
- Fellow time spent in the clinical setting that is supported through grant funds must not be billed as patient care.
For more information, visit Pfizer.
